|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300069142 |
|
最近更新日期: Date of Last Refreshed on: |
2023-03-08 02:50:08 |
|
注册时间: Date of Registration: |
2023-03-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
鼻咽癌放疗后张口困难临床防控路径的构建 |
|
Public title: |
Construction of clinical prevention and control path for radiation-induced trismus in nasopharyngeal carcinoma |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
鼻咽癌放疗后张口困难临床防控路径的构建 |
|
Scientific title: |
Construction of clinical prevention and control path for radiation-induced trismus in nasopharyngeal carcinoma |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
曾谷清 |
研究负责人: |
王婷 |
|
Applicant: |
Guqing Zeng |
Study leader: |
Ting Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 15673427900 |
研究负责人电话: Study leader's telephone: |
+86 17873471540 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zengguqing0123@163.com |
研究负责人电子邮件: Study leader's E-mail: |
1819990742@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南省衡阳市蒸湘区常胜西路28号 |
研究负责人通讯地址: |
湖南省衡阳市蒸湘区常胜西路28号 |
|
Applicant address: |
28 West Changsheng Road, Hengyang, Hunan |
Study leader's address: |
28 West Changsheng Road, Hengyang, Hunan |
|
申请注册联系人邮政编码: Applicant postcode: |
421001 |
研究负责人邮政编码: Study leader's postcode: |
421001 |
|
申请人所在单位: |
湖南省衡阳市南华大学护理学院 |
||
|
Applicant's institution: |
School of Nursing, University of South China, Hengyang, Hunan |
||
|
研究负责人所在单位: |
湖南省衡阳市南华大学护理学院 |
||
|
Affiliation of the Leader: |
School of Nursing, University of South China, Hengyang, Hunan |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022-USC-HL-224 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南华大学医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee University of south china |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-12-13 00:00:00 |
||
|
伦理委员会联系人: |
刘良专 |
||
|
Contact Name of the ethic committee: |
Liangzhuan Liu |
||
|
伦理委员会联系地址: |
湖南省衡阳市蒸湘区常胜西路28号 |
||
|
Contact Address of the ethic committee: |
28 West Changsheng Road, Hengyang, Hunan |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 734 8282726 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南华大学护理学院 |
||||||||||||||||||||||
|
Primary sponsor: |
School of nursing University of South China |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖南省衡阳市蒸湘区常胜西路28号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
28 West Changsheng Road, Hengyang, Hunan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2021年湖南省自然科学基金面上项目(项目编号:2021JJ30586) |
||||||||||||||||||||||
|
Source(s) of funding: |
General Program of Hunan Natural Science Foundation(No.2021JJ30586) |
||||||||||||||||||||||
|
Target disease: |
nasopharyngeal carcinoma |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
半随机对照 |
||||||||||||||||||||||
|
Study design: |
Quasi-randomized controlled |
||||||||||||||||||||||
|
研究目的: |
1.通过规范文献检索,对当前鼻咽癌放疗后张口困难筛查、护理、治疗证据进行总结; 2.通过质性访谈,全面了解衡阳市当前鼻咽癌放疗后张口困难防控现况,分析路径实施存在问题; 3.构建基于三级预防理念的鼻咽癌放疗后张口困难的防控措施与临床防控路径。 |
||||||||||||||||||||||
|
Objectives of Study: |
1.To summarize the evidence of screening, nursing and treatment of difficulty in mouth opening of nasopharyngeal carcinoma after radiotherapy by standardizing literature search. 2.To fully understand the current situation of difficult prevention and control of radiation-induced trismus of nasopharyngeal carcinoma in Hengyang City and analyze the problems in the implementation of the path. 3.To construct the prevention and control measures and clinical prevention and control pathway of difficulty in radiation-induced trismus of nasopharyngeal carcinoma based on the concept of tertiary prevention. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
质性访谈 |
||||||||||||||||||||||
|
Inclusion criteria |
Qualitative interview |
||||||||||||||||||||||
|
排除标准: |
质性访谈 |
||||||||||||||||||||||
|
Exclusion criteria: |
Qualitative interview |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-02-01 00:00:00至 To 2024-01-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-04-01 00:00:00 至 To 2023-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
选取衡阳市某三甲医院放疗科鼻咽癌放疗患者72例为研究对象。根据随机数字表法分为对照组和干预组。具体随机方案:①编号:将研究对象按入院先后顺序进行编号(01-72号);②产生随机数:从随机数字表的第2行第1列开始依次取72个随机数(重复数字跳过)赋予患者编号,再将随机数由小到大依次编号;③随机分组:规定随机数字秩次1-36为对照组,37-72为干预组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The researcher used random number table to generate random numbers: ① Number: Number the subjects according to the order of admission (No. 01-72); ② Generate random number: from the second row and the first column of the random number table, take 72 random numbers (skip repeated numbers) and assign them |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
未说明 |
|
Blinding: |
Not stated |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2024年6月1日,临床试验公共管理平台,http://www.medresman.org |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
June 1, 2024, ResMan, a public management platform for clinical trials, http://www.medresman.org |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表和电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form and Electronic Data Capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |